Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	HER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 1 / Phase 2	2026-01-23		NCT03368729

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Breast Cancer Research Foundation of Alabama	2
Susan G. Komen Breast Cancer Foundation	16
Tesaro, Inc.	16
The V Foundation	8
Translational Breast Cancer Research Consortium	19
University of Alabama at Birmingham	467

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Mayo Clinic	Rochester	United States	664
Montefiore	The Bronx	United States	4
University of Alabama at Birmingham	Birmingham	United States	247
University of Chicago	Chicago	United States	312
University of North Carolina	Chapel Hill	United States	101
University of Pennsylvania	Philadelphia	United States	507
University of Washington-	Seattle	United States	1